Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | BRAF |
Variant | E275K |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | BRAF E275K lies within the phorbol-ester/DAG-type zinc finger domain of the Braf protein (UniProt.org). E275K results in decreased phosphorylation of Mek and Erk in one study (PMID: 19206169), but increased phosphatidylserine binding, moderately increased Mek phosphorylation, weak transforming activity in culture, and altered zebrafish embryo development in another study (PMID: 36347258), and demonstrates cell proliferation and viability similar to wild-type Braf in culture (PMID: 29533785), and therefore, its effect on Braf protein function is unknown. |
Associated Drug Resistance | |
Category Variants Paths |
BRAF mutant BRAF E275K |
Transcript | NM_004333.6 |
gDNA | chr7:g.140801449C>T |
cDNA | c.823G>A |
Protein | p.E275K |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_047420767.1 | chr7:g.140801449C>T | c.823G>A | p.E275K | RefSeq | GRCh38/hg38 |
NM_001354609.1 | chr7:g.140801449C>T | c.823G>A | p.E275K | RefSeq | GRCh38/hg38 |
NM_004333.5 | chr7:g.140801449C>T | c.823G>A | p.E275K | RefSeq | GRCh38/hg38 |
NM_001354609.2 | chr7:g.140801449C>T | c.823G>A | p.E275K | RefSeq | GRCh38/hg38 |
XM_005250045 | chr7:g.140801449C>T | c.823G>A | p.E275K | RefSeq | GRCh38/hg38 |
XM_047420768.1 | chr7:g.140801449C>T | c.823G>A | p.E275K | RefSeq | GRCh38/hg38 |
NM_001378474.1 | chr7:g.140801449C>T | c.823G>A | p.E275K | RefSeq | GRCh38/hg38 |
XM_017012559.2 | chr7:g.140801449C>T | c.823G>A | p.E275K | RefSeq | GRCh38/hg38 |
NM_001374258.1 | chr7:g.140801449C>T | c.823G>A | p.E275K | RefSeq | GRCh38/hg38 |
XM_017012558 | chr7:g.140801449C>T | c.823G>A | p.E275K | RefSeq | GRCh38/hg38 |
NM_001374244.1 | chr7:g.140801449C>T | c.823G>A | p.E275K | RefSeq | GRCh38/hg38 |
NM_001378469.1 | chr7:g.140801449C>T | c.823G>A | p.E275K | RefSeq | GRCh38/hg38 |
NM_004333.6 | chr7:g.140801449C>T | c.823G>A | p.E275K | RefSeq | GRCh38/hg38 |
NM_001378471.1 | chr7:g.140801449C>T | c.823G>A | p.E275K | RefSeq | GRCh38/hg38 |
XM_047420769.1 | chr7:g.140801449C>T | c.823G>A | p.E275K | RefSeq | GRCh38/hg38 |
NM_001378468.1 | chr7:g.140801449C>T | c.823G>A | p.E275K | RefSeq | GRCh38/hg38 |
XM_017012558.1 | chr7:g.140801449C>T | c.823G>A | p.E275K | RefSeq | GRCh38/hg38 |
XM_017012559 | chr7:g.140801449C>T | c.823G>A | p.E275K | RefSeq | GRCh38/hg38 |
NM_004333 | chr7:g.140801449C>T | c.823G>A | p.E275K | RefSeq | GRCh38/hg38 |
XM_017012559.1 | chr7:g.140801449C>T | c.823G>A | p.E275K | RefSeq | GRCh38/hg38 |
NM_001378470.1 | chr7:g.140800417C>T | c.823G>A | p.E275K | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|